Unlocking an Affordable Future: Key #3 Support and Equip Clinicians ENHANCE PATIENT OUTCOMES AND IMPROVE THE PATIENT EXPERIENCE At the core of the pharmacy benefit specialty function lies expertise used to ensure the right patient gets the right drug in
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. The Latest in Rx News: Why are insulin prices so high?
(Washington, D.C.) — As Congress begins to examine high prescription drug prices, the Pharmaceutical Care Management Association (PCMA) sent letters to several congressional committees highlighting the value pharmacy benefit managers (PBMs) provide to patients and payers as well as outlining
Pharmacy Direct and Indirect Remuneration (DIR) Value-based Pharmacy Reimbursement Reduces Drug Costs for Medicare Beneficiaries, Lowers Spending. Pharmacy direct and indirect remuneration, or Pharmacy DIR, is a form of value-based contracting in Medicare Part D. Pharmacy DIR increases the quality
Executive Vice President, CVS Health President, CVS Caremark Alan Lotvin, M.D., is executive vice president of CVS Health, and president of CVS Caremark, the company’s pharmacy benefits management (PBM) business. In this role, Dr. Lotvin oversees all aspects of the
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on litigation, filed in the U.S. District Court of the District of Columbia, regarding the Trump administration’s final rule Transparency in Coverage: To avoid higher prescription drug costs for
A recent blog (“Payers and PBMs Profit from Obscure Pharmacy Fees, While Seniors See No Relief in Prescription Costs”) suggests performance-based price concessions are retained by PBMs, restrict the growth of independent pharmacies, and inflate Medicare Part D enrollee’s out-of-pocket costs—unfounded
©2024 PCMA. All Rights Reserved.
